Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 29, 2007

Durect and Hospira Sign Posidur Manufacturing Agreement

  • Hospira Worldwide will supply Durect with its Phase II post-surgical pain management drug, Posidur ™. According to the long-term manufacturing and supply agreement, Hospira's One 2 One® contract manufacturing services will provide clinical and commercial supplies on a worldwide basis.

    "Hospira's capabilities, expertise and capacity in manufacturing parenteral products makes them an ideal partner for us," says James Brown, CEO of DURECT. “The establishment of this agreement, following on the heels of our recent development and commercialization collaboration with Nycomed, now one of the 25 largest pharmaceutical companies in the world as a result of its Altana acquisition, is a second key milestone in our POSIDUR development program.”

    Posidur is intended to be injected during surgery, where it continuously releases therapeutic levels of bupivacaine in a controlled fashion, providing up to 72 hours of uninterrupted local analgesia, according to Durect.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »